Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Yang, Ge"'
Autor:
Yan Zhang, Yang Ge, Yun-Bo Zhao, Chuanhua Zhao, Jing Zhou, Lin Zhao, Shikai Wu, Yusheng Wang, Kaili Yang, Lu Han, Qin Li
Publikováno v:
Journal of Clinical Oncology. 39:e15585-e15585
e15585 Background: A previous phase 1b trial has shown encouraging efficacy of regorafenib plus nivolumab in patients with microsatellite stable/mismatch repair proficient (MSS/pMMR) metastatic colorectal cancer (mCRC). We aimed to evaluate the effic
Autor:
Nancy Y. Lee, Irene Brana, Rebecca D. Chernock, Robert I. Haddad, Ravindra Uppaluri, William H. Westra, Douglas Adkins, Ramona F. Swaby, Joy Yang Ge, Arkadiy Klochikhin, Amichay Meirovitz, Sufia Safina, Behzad Bidadi, Christophe Le Tourneau, Ezra E.W. Cohen, Stéphane Temam
Publikováno v:
Journal of Clinical Oncology. 37:TPS6090-TPS6090
TPS6090 Background: Evidence of efficacy and pathological response at the time of surgery was reported in two phase 2 studies (NCT02296684 and NCT02641093) of preoperative pembrolizumab in patients with high-risk, resectable, locally advanced (LA) he
Autor:
Ramona F. Swaby, Joy Yang Ge, Jessica L. Geiger, Gregory A. Daniels, Burak Gumuscu, Anne Lynn S. Chang, Ezra E.W. Cohen
Publikováno v:
Journal of Clinical Oncology. 37:TPS9597-TPS9597
TPS9597 Background: Among patients with high-risk, locally advanced (LA) cutaneous squamous cell carcinoma (cSCC) who receive current standard-of-care surgical resection and adjuvant radiotherapy, ~40-50% develop local recurrence and regional metasta
Autor:
Lillian L. Siu, Chia Jui Yen, Behzad Bidadi, Jean-Pierre Delord, John Waldron, Sadakatsu Ikeda, Vincent Grégoire, Sanjiv S. Agarwala, Jeffrey Yorio, Danny Rischin, Joy Yang Ge, Yungan Tao, Lisa Licitra, Barbara Burtness, Holly Brown, Ruey-Long Hong, Sercan Aksoy, Jean-Pascal Machiels
Publikováno v:
Journal of Clinical Oncology. 36:TPS6094-TPS6094
TPS6094Background: Preclinical data in murine cancer models show improved tumor growth control and survival when radiation therapy (RT) is combined with a PD-1 inhibitor. Pembrolizumab is effective...
Autor:
Yufan Zhao, Hema Gowda, Ezra E.W. Cohen, Fan Jin, Jan B. Vermorken, David G. Pfister, Joy Yang Ge, Danny Rischin, Kevin J. Harrington
Publikováno v:
Journal of Clinical Oncology. 36:TPS6090-TPS6090
TPS6090Background: Although the EXTREME regimen is a Category 1 evidence-supported combination recommended by NCCN guidelines as first-line (1L) treatment for patients with R/M SCCHN, it is associa...
Autor:
Shirish M. Gadgeel, Hossein Borghaei, Matthew A. Gubens, Amit Panwalkar, Lecia V. Sequist, Corey J. Langer, Harry Raftopoulos, Amita Patnaik, Mark M. Awad, Steven Francis Powell, Shadia I. Jalal, Leena Gandhi, Joseph Fiore, Renato Martins, James P. Stevenson, Joy Yang Ge, Vassiliki A. Papadimitrakopoulou, James Chih-Hsin Yang, Ryan D. Gentzler
Publikováno v:
Journal of Clinical Oncology. 35:9094-9094
9094 Background: Data from the randomized, phase 2 cohort G of KEYNOTE-021 (NCT02039674) showed that adding pembro to first-line CP in patients (pts) with advanced nonsquamous NSCLC significantly improved the primary end point of ORR (55% vs 29%, P =
Autor:
James P. Stevenson, Amita Patnaik, Corey J. Langer, Steven Francis Powell, Liza C. Villaruz, Matthew A. Gubens, Hossein Borghaei, Shirish M. Gadgeel, Joseph Fiore, Joy Yang Ge, Leena Gandhi, Harry Raftopoulos, Shadia I. Jalal, Lecia V. Sequist
Publikováno v:
Journal of Clinical Oncology. 34:9027-9027
9027Background: The checkpoint inhibitor combination pembro (anti–PD-1) + ipi (anti–CTLA-4) yielded promising antitumor activity and manageable toxicity in previously treated NSCLC patients (pts) i...
Autor:
David S. Siegel, Enrique M. Ocio, Maria-Victoria Mateos, Jesús F. San Miguel, Donna E. Reece, David Avigan, Nikhil C. Munshi, Patricia Marinello, Paula Rodriguez-Otero, Joy Yang Ge, Jatin J. Shah, Philippe Moreau, Robert Z. Orlowski
Publikováno v:
Journal of Clinical Oncology. 34:8010-8010
8010Background: Pembrolizumab (pembro) is a monoclonal antibody against PD-1 that helps to restore antitumor immune surveillance. KEYNOTE-023 (NCT02036502) is a phase 1 dose-escalation study evalua...
Autor:
Shirish M. Gadgeel, Joy Yang Ge, Leena Gandhi, Lecia V. Sequist, Liza C. Villaruz, Matthew A. Gubens, Amita Patnaik, James P. Stevenson, Vassiliki A. Papadimitrakopoulou, Corey J. Langer, James Chih-Hsin Yang, Robert Bachman, Harry Raftopoulos, Ralph J. Hauke, Hossein Borghaei
Publikováno v:
Journal of Clinical Oncology. 34:9016-9016
9016Background: The anti–PD-1 antibody pembro exhibits robust antitumor activity in patients (pts) with advanced NSCLC. In cohorts A-C of KEYNOTE-021 (NCT02039674), we evaluated the efficacy and sa...
Autor:
Amita Patnaik, Hossein Borghaei, James Chih-Hsin Yang, Jennifer Bourque, James P. Stevenson, Ellie Im, Leena Gandhi, Robert Bachman, Matthew A. Gubens, Shirish M. Gadgeel, Vassiliki A. Papadimitrakopoulou, Lecia V. Sequist, Joy Yang Ge
Publikováno v:
Journal of Clinical Oncology. 33:8031-8031
8031 Background: As monotherapy, the anti–PD-1 antibody pembro has shown robust antitumor activity in advanced NSCLC patients (pts). KEYNOTE-021 evaluated the safety, tolerability, and clinical act...